Azomycin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 462918

CAS#: 527-73-1

Description: Azomycin is a natural antimicrobial antibiotic produced by a strain of Streptomyces eurocidicus. It has been used to combat anaerobic bacterial and parasitic infections.

Chemical Structure

img
Azomycin
CAS# 527-73-1
Instruction

Theoretical Analysis

MedKoo Cat#: 462918
Name: Azomycin
CAS#: 527-73-1
Chemical Formula: C3H3N3O2
Exact Mass: 113.02
Molecular Weight: 113.076
Elemental Analysis: C, 31.87; H, 2.67; N, 37.16; O, 28.30

Price and Availability

Size Price Availability Quantity
1g USD 250 2 Weeks
5g USD 550 2 Weeks
Bulk inquiry

Synonym: Amicin; 2-Nitroimidazole;

IUPAC/Chemical Name: 2-nitro-1H-imidazole

InChi Key: YZEUHQHUFTYLPH-UHFFFAOYSA-N

InChi Code: InChI=1S/C3H3N3O2/c7-6(8)3-4-1-2-5-3/h1-2H,(H,4,5)

SMILES Code: [O-][N+](C1=NC=CN1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 113.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kallitsakis MG, Ioannou DI, Terzidis MA, Kostakis GE, Lykakis IN. Selective Photoinduced Reduction of Nitroarenes to N-Arylhydroxylamines. Org Lett. 2020 Jun 5;22(11):4339-4343. doi: 10.1021/acs.orglett.0c01367. Epub 2020 May 26. PMID: 32453579.

2: Meißner R, Feketeová L, Ribar A, Fink K, Limão-Vieira P, Denifl S. Electron Ionization of Imidazole and Its Derivative 2-Nitroimidazole. J Am Soc Mass Spectrom. 2019 Dec;30(12):2678-2691. doi: 10.1007/s13361-019-02337-w. Epub 2019 Oct 30. PMID: 31667709; PMCID: PMC6914720.

3: Abinaya M, Rajakumaran R, Chen SM, Karthik R, Muthuraj V. In Situ Synthesis, Characterization, and Catalytic Performance of Polypyrrole Polymer-Incorporated Ag2MoO4 Nanocomposite for Detection and Degradation of Environmental Pollutants and Pharmaceutical Drugs. ACS Appl Mater Interfaces. 2019 Oct 16;11(41):38321-38335. doi: 10.1021/acsami.9b13682. Epub 2019 Oct 3. PMID: 31549800.

4: Hedges JB, Ryan KS. In vitro Reconstitution of the Biosynthetic Pathway to the Nitroimidazole Antibiotic Azomycin. Angew Chem Int Ed Engl. 2019 Aug 19;58(34):11647-11651. doi: 10.1002/anie.201903500. Epub 2019 Jul 17. PMID: 31231913.

5: Nakata N, Kiriu M, Okumura Y, Zhao S, Nishijima KI, Shiga T, Tamaki N, Kuge Y, Matsumoto H. Comparative evaluation of [18F]DiFA and its analogs as novel hypoxia positron emission tomography and [18F]FMISO as the standard. Nucl Med Biol. 2019 Mar;70:39-45. doi: 10.1016/j.nucmedbio.2019.01.008. Epub 2019 Feb 8. PMID: 30836255.

6: Maier FC, Schweifer A, Damaraju VL, Cass CE, Bowden GD, Ehrlichmann W, Kneilling M, Pichler BJ, Hammerschmidt F, Reischl G. 2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging. Pharmaceuticals (Basel). 2019 Feb 15;12(1):31. doi: 10.3390/ph12010031. PMID: 30781409; PMCID: PMC6469291.

7: Sun W, Falzon C, Naimi E, Akbari A, Wiebe LI, Tandon M, Kumar P. Synthesis of [18F]FAZA Using Nosyl and Iodo Precursors for Nucleophilic Radiofluorination. Curr Radiopharm. 2019;12(1):49-57. doi: 10.2174/1874471011666181019105947. PMID: 30338747.

8: Ficociello G, Zonfrilli A, Cialfi S, Talora C, Uccelletti D. Yeast-Based Screen to Identify Natural Compounds with a Potential Therapeutic Effect in Hailey-Hailey Disease. Int J Mol Sci. 2018 Jun 20;19(6):1814. doi: 10.3390/ijms19061814. PMID: 29925776; PMCID: PMC6032253.

9: Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure- cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2018 Feb 1;73(2):265-279. doi: 10.1093/jac/dkx351. PMID: 29077920.

10: Busk M, Munk OL, Jakobsen SS, Horsman MR. Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity. Acta Oncol. 2017 Nov;56(11):1583-1590. doi: 10.1080/0284186X.2017.1355114. Epub 2017 Aug 25. PMID: 28840765.

11: Kumar P, Roselt P, Reischl G, Cullinane C, Beiki D, Ehrlichmann W, Binns D, Naimi E, Yang J, Hicks R, Machulla HJ, Wiebe LI. β -[18F]Fluoro Azomycin Arabinoside (β -[18F]FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors. Curr Radiopharm. 2017;10(2):93-101. doi: 10.2174/1874471010666170313120540. PMID: 28294075.

12: Schweifer A, Maier F, Ehrlichmann W, Lamparter D, Kneilling M, Pichler BJ, Hammerschmidt F, Reischl G. [18F]Fluoro-azomycin-2´-deoxy-β-d- ribofuranoside - A new imaging agent for tumor hypoxia in comparison with [18F]FAZA. Nucl Med Biol. 2016 Dec;43(12):759-769. doi: 10.1016/j.nucmedbio.2016.08.005. Epub 2016 Aug 9. PMID: 27693670.

13: Wanek T, Kreis K, Križková P, Schweifer A, Denk C, Stanek J, Mairinger S, Filip T, Sauberer M, Edelhofer P, Traxl A, Muchitsch VE, Mereiter K, Hammerschmidt F, Cass CE, Damaraju VL, Langer O, Kuntner C. Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[18F]fluoro-β-d- allofuranosyl)-2-nitroimidazole (β-6'-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia. Bioorg Med Chem. 2016 Nov 1;24(21):5326-5339. doi: 10.1016/j.bmc.2016.08.053. Epub 2016 Aug 29. PMID: 27614920.

14: Kumar P, Elsaidi HR, Zorniak B, Laurens E, Yang J, Bacchu V, Wang M, Wiebe LI. Synthesis and Biological Evaluation of Iodoglucoazomycin (I-GAZ), an Azomycin-Glucose Adduct with Putative Applications in Diagnostic Imaging and Radiotherapy of Hypoxic Tumors. ChemMedChem. 2016 Aug 5;11(15):1638-45. doi: 10.1002/cmdc.201600213. Epub 2016 Jul 5. PMID: 27377671; PMCID: PMC5095876.

15: Aksoy Gökmen A, Girginkardeşler N, Kilimcioğlu AA, Şirin MC, Özbilgin A. Trichomonas vaginalis'in metronidazol, ornidazol ve proton pompa inhibitörleri pantoprazol ve esomeprazole karşı in vitro duyarlılığı [In vitro susceptibility of Trichomonas vaginalis to metronidazole, ornidazole and proton pump inhibitors pantoprazole and esomeprazole]. Mikrobiyol Bul. 2016 Jan;50(1):133-9. Turkish. PMID: 27058337.

16: Zhou F, Zanganeh S, Mohammad I, Dietz C, Abuteen A, Smith MB, Zhu Q. Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye- conjugate with improved fluorescent yield. Org Biomol Chem. 2015 Dec 14;13(46):11220-7. doi: 10.1039/c5ob01460c. PMID: 26403518; PMCID: PMC4651866.

17: Quan S, Wang Y, Zhou A, Kumar P, Narain R. Galactose-based Thermosensitive Nanogels for Targeted Drug Delivery of Iodoazomycin Arabinofuranoside (IAZA) for Theranostic Management of Hypoxic Hepatocellular Carcinoma. Biomacromolecules. 2015 Jul 13;16(7):1978-86. doi: 10.1021/acs.biomac.5b00576. Epub 2015 Jun 3. PMID: 25996799.

18: Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner GC, Ngan SY, Chander S, Powell GJ, Herschtal A, Te Marvelde L, Desai J, Choong PF, Stacker SA, Achen MG, Ferris N, Fox S, Slavin J, Thomas DM. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer. 2014 Dec 9;111(12):2254-61. doi: 10.1038/bjc.2014.537. Epub 2014 Oct 16. PMID: 25321190; PMCID: PMC4264446.

19: Leitsch D, Schlosser S, Burgess A, Duchêne M. Nitroimidazole drugs vary in their mode of action in the human parasite Giardia lamblia. Int J Parasitol Drugs Drug Resist. 2012 May 12;2:166-70. doi: 10.1016/j.ijpddr.2012.04.002. PMID: 24533278; PMCID: PMC3862438.

20: Wuest M, Kumar P, Wang M, Yang J, Jans HS, Wiebe LI. In vitro and in vivo evaluation of [(18)F]F-GAZ, a novel oxygen-mimetic azomycin-glucose conjugate, for imaging hypoxic tumor. Cancer Biother Radiopharm. 2012 Oct;27(8):473-80. doi: 10.1089/cbr.2011.1148. Epub 2012 Jun 29. PMID: 22746267.